Enzo Biochem (NYSE:ENZ) Research Coverage Started at StockNews.com

Research analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a note issued to investors on Saturday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Trading Down 1.8 %

Enzo Biochem stock opened at $1.12 on Friday. Enzo Biochem has a one year low of $0.99 and a one year high of $1.50. The stock has a fifty day moving average of $1.12 and a 200 day moving average of $1.13.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ENZ. XTX Topco Ltd lifted its position in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares in the last quarter. Wittenberg Investment Management Inc. purchased a new position in Enzo Biochem during the fourth quarter valued at $95,000. Finally, Renaissance Technologies LLC lifted its position in Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares in the last quarter. Hedge funds and other institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.